## **Research Article**

## The impact of ERP29 on the progression of pharyngeal squamous cell carcinoma

Juliana Carron<sup>a</sup>, Lilian de Oliveira Coser<sup>b</sup>, Andrea Kelemen<sup>c,d</sup>, Genrich V Tolstonog<sup>c,d</sup>, Carmen Silvia Passos Lima<sup>a,e</sup>, Gustavo Jacob Lourenço<sup>a</sup>

<sup>a</sup> Laboratory of Cancer Genetics, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
<sup>b</sup> Laboratory of Nerve Regeneration, Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, São Paulo, Brazil
<sup>c</sup> Department of Otolaryngology - Head and Neck Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
<sup>d</sup> Agora Cancer Research Centre, Lausanne, Switzerland
<sup>e</sup> Department of Anesthesiology, Oncology and Radiology, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil

## **Corresponding author**

Gustavo Jacob Lourenço, Laboratory of Cancer Genetics, School of Medical Sciences, University of Campinas, 50 Vital Brasil Street, Barão Geraldo, Campinas, São Paulo, Brazil. Postal-code: 13083-888. E-mail: guslour@unicamp.br https://orcid.org/0000-0002-5944-0305

## Abstract

**Objectives**: We investigated *ERP29* gene role on pharynx squamous cell carcinoma (PSCC) progression in cisplatin (CDDP)-sensitive (FaDu and LAU-2063), CDDP-treated (FaDu-CDDP), and CDDP-resistant (FaDu-R) cells.

**Materials and Methods**: Cells, modified to induce *ERP29* overexpression or silencing, were mainly submitted to cell proliferation, necrosis, and migration assay. E-cadherin immunoexpression was assessed in three-dimensional spheroids. WNT, MAPK, and PI3K/AKT pathways genes' expression were identified by PCR array and validated by qPCR. The influence of microRNA miR-4421 inhibitor on *ERP29* expression, and its target genes, were quantified by qPCR.

**Results**: *ERP29* silencing especially decreased necrotic cell death and increased migration in CDDP-sensitive, treated, and resistant cells, and decreased E-cadherin immunoexpression in CDDP-sensitive three-dimensional-spheroids. During CDDP treatment, *ERP29* silencing increased cell proliferation. In CDDP-sensitive cells, *ERP29* silencing increased the expression of several genes involved in WNT, MAPK, and PI3K/AKT pathways and decreased *CASP9* expression. During CDDP treatment, *ERP29* silencing decreased *MDM2* and *CASP9* expression. In CDDP-resistant cells, *ERP29* silencing increased *SOS1*, *MAPK1*, *AKT1*, *ITGAV*, and *CCNE1*; and decreased *KRAS*, *JUN*, *MDM2*, and *CASP9* expression. In addition, miR-4421 inhibition increased *ERP29* expression and decreased *MAPK1*, *AKT1*, and *JUN* expression in CDDP-sensitive cells; and *SOS1*, *MAPK1*, *AKT1*, and *ITGAV* in CDDP-resistant cells, suggesting a potential therapeutic use for miR-4421 inhibitor. **Conclusions**: *ERP29* silencing seems to decrease necrosis and increase migration of PSCC cells by modulating genes enrolled in WNT, MAPK, and PI3K/AKT pathways. Once validated, our data may enable target therapy development based on ensuring *ERP29* expression that could benefit patients with CDDP-sensitive and resistant tumors.

**Keywords**: pharynx squamous cell carcinoma; *ERP29*; cisplatin resistance; cell necrosis; cell migration

### Introduction

Pharynx squamous cell carcinoma (PSCC), comprising the oropharynx, nasopharynx, and hypopharynx locations, is responsible for 316,020 new cases and 166,750 deaths per year worldwide [1]. Smoking and drinking chronic habits [2] and HPV infection [3] are known risk factors for developing the disease. Additionally, inherited and acquired genetic alterations play important roles in pharynx cancer risk and progression [4-7].

Patients' overall survival remains likely unchanged in the last decades, and cisplatin (CDDP) resistance is one of the major responsible for therapy failure [8, 9]. Tumor cells acquire CDDP resistance by developing a complex self-defense mechanism against cytotoxic compounds, increasing CDDP detoxification, inhibiting apoptosis and modifying gene and microRNA (miRNA) expression patterns [9].

Mutations in WNT, MAPK, and PI3K/AKT signaling pathways are commonly found in PSCC and are responsible for increasing cell proliferation, survival, and migration [10-12]. Moreover, genetic mutation and instability in the carcinogenesis process promote a high protein demand and leads to cell hemostasis perturbation in the endoplasmic reticulum (ER), involved in protein production, folding, maturation, and degradation [13]. In PSCC, decreased ER stress was associated with increased cell proliferation and decreased apoptosis [14-16].

Resident of the ER, the endoplasmic reticulum protein 29 (ERp29) is a chaperone protein, codified by the *ERP29* gene, that contributes to protein biogenesis, folding, and secretion [17]. In addition, when ER folding fails, leading to the accumulation of unfolded proteins and activation of other chaperones such as heat shock 70 kDa protein 5 (*GRP78*) and heat shock protein 90 beta family member 1 (*GRP94*), ERp29 mediates the unfolded protein response (UPR) to alleviate ER stress and to restore homeostasis [18].

The effects of *ERP29* expression in tumors seem tissue-specific and are controversial [19]. Previous studies have shown that *ERP29* silencing increased cell proliferation in the breast [20, 21], colorectal, lung, bladder, prostate, ovary, hepatic, skin [21], and gastric [22] cancers. In contrast, *ERP29* silencing was associated with decreased cell proliferation in other studies of breast, lung, cervical, melanoma [23], hepatic [24], promyelocytic leukemia [25], and colorectal [26] cancers. Additionally, *ERP29* silencing increased the expression of genes involved in WNT, MAPK, and PI3K/AKT signaling, as glycogen synthase kinase 3 beta (*GSK3B*), epidermal growth factor receptor (*EGFR*), plasminogen activator urokinase

receptor (*uPAR*), mitogen-activated protein kinase 3 (*ERK1*), mitogen-activated protein kinase 1 (*MAPK1*), phosphoinositide-3-kinase C (*PI3K*), cyclin D2 (*CCND2*), activating transcription factor 4 (*ATF4*) and caspase 3 (*CASP3*), respectively, and genes involved in cell adhesion, as E-cadherin (*CDH1*), tight junction protein 1 (*ZO-1*), and par-3 family cell polarity regulator (*PAR3*), influencing cell invasion and migration in the breast [20, 27, 28] and gastric [22, 29] cancers. Likewise, inhibition of *ERP29* was associated with recurrence and metastasis in the breast, melanoma, gastric [19], pancreatic [30], hepatic [31], and colorectal cancers [19, 32].

Furthermore, decreased survival against genotoxic stress induced by doxorubicin in breast cancer [33] and by radiation in nasopharyngeal cancer [34] was also attributed to *ERP29* silencing. *ERP29* silencing was previously associated with CDDP sensitivity in *TP53* mutated lung cancer, although the exact mechanisms were not explored [35].

A previous study conducted by our group found that the single nucleotide variation (SNV) rs7114, located at the 3'- untranslated region of *ERP29*, was associated with a 6-fold increase in oropharynx squamous cell carcinoma risk, and a 2-fold decrease in patients' survival [36]. The SNV induced *ERP29* inhibition possibly by increasing the binding affinity of miRNA miR-4421 to *ERP29*, decreasing *ERP29* expression and ERp29 protein production as consequence [36]. However, the mechanisms by which *ERP29* acted in tumor carcinogenesis and outcome of patients were not sufficiently elucidated in the study.

This study aimed to examine the role of *ERP29* in the progression of PSCC in sensitive cells, treated, and resistant to CDDP. To achieve this goal, we investigated ER stress, cell cycle, proliferation, apoptosis, necrosis, migration, and E-cadherin immunoexpression in pharyngeal cancer cells manipulated to either overexpress or silence *ERP29*. Additionally, we identified genes that were regulated by *ERP29* and assessed the effects of miR-4421 inhibition on their expression.

#### **Material and Methods**

### Cell culture and CDDP resistance establishment

FaDu cell line (HTB-43<sup>TM</sup>, American Type Culture Collection<sup>®</sup>) CDDP-sensitive was cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco) and 100 U/mL penicillin and streptomycin (P/S, Gibco). To evaluate CDDP treatment in FaDu cells, to simulate patients

undergoing treatment, during the following experiments FaDu cells were cultured in DMEM supplemented with 10% FBS, 1% P/S, and 5 µM CDDP (CITOPLAX<sup>®</sup>, Bergamo, Taboão da Serra, BRA) (from now on, FaDu treated with CDDP will be abbreviated as FaDu-CDDP). Furthermore, to evaluate CDDP resistance in FaDu cells, to simulate patients with resistant tumors, we developed CDDP-resistant FaDu from the parental FaDu cells that were subjected to gradient exposure to CDDP as described in Naik *et al.* (2018) [37] (from now on, FaDu CDDP-resistant will be abbreviated as FaDu-R).

LAU-2063 cell line CDDP-sensitive was established from hypopharyngeal squamous cell carcinoma obtained from a male patient undergoing surgery at the Lausanne University Hospital (CHUV) (under protocol approved by the Cantonal Department of the Swiss Ethics Committees). LAU-2063 was cultured in DMEM (Gibco) supplemented with 5% FBS (Gibco) and 100 U/mL P/S (Gibco), and was used to validate the effect of *ERP29* silencing in cell migration.

All cells were cultured in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C (Thermo Scientific, Waltham, MA, USA).

### Drug sensitivity assay

FaDu and FaDu-R cells were plated in 96-well flat-bottom culture plate (1.5 x 10<sup>3</sup> cells/well) and incubated with CDDP (0.5 and 1.0  $\mu$ M) for 72 h. The effect of CDDP on cell viability was studied using Cell Counting Kit 8 (CCK-8, Sigma-Aldrich, St. Louis, MO, USA) reagent by measuring the optical density at 450 nm using the microplate reader spectrophotometer Epoch (BioTek, Shoreline, WA, USA).

### Three-dimensional (3D) cell culture

In brief, 1 x 10<sup>4</sup> FaDu cells were admixed into Matrigel (1:3 ratio) (Corning, Corning, NY, USA) before seeding them in one well of a poly-HEMA-coated 8-well chamber slide slide (LabTek Chamber Slide, Thermo Scientific). After 30 min incubation at 37°C, DMEM supplemented with 10% FBS and 100 U/mL P/S was added, and cells were kept in culture for six days to allow the development of spheroids. Spheroids-containing Matrigel were collected for immunofluorescence staining.

### Induction of ERP29 overexpression and silencing

*ERP29* mRNA (NM\_006817) was inserted into pcDNA3.1(+)-N-eGFP expression vector (GenScript<sup>®</sup>, Piscataway, NJ, USA) to induce *ERP29* overexpression. Empty pcDNA3.1(+)-N-eGFP vector was used as the control for overexpression analysis. To induce *ERP29* silencing, a small interfering RNA (siRNA) specific for *ERP29* was used (assay ID s21576, Invitrogen, Waltham, MA, USA) as described in Chen *et al.* (2015) [38]. Negative control siRNA was used as the control for silencing analysis (assay ID 4390843, Invitrogen). Cells were transiently transfected with 1  $\mu$ g of *ERP29* expression vector or empty vector, or with 50  $\mu$ M of *ERP29* siRNA or negative control siRNA using Lipofectamine 3000 (Invitrogen). The effectiveness of transfection was monitored by green fluorescent protein (GFP) detection with flow cytometer NovoCyte (ACEA Biosciences, San Diego, CA, USA).

## Gene expression by quantitative PCR (qPCR)

Cells were harvested and total RNA was extracted with TRIzol reagent (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. cDNA was generated using SuperScript III reagents (Life Technologies). Experiments were performed using SYBR Green PCR Master Mix reagents (Applied Biosystems, Bedford, MA, USA) and specific primers, in triplicate per sample, and a negative control without template was included in each plate. Gene relative expression level was normalized to the reference housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) using the  $2^{-\Delta\Delta Ct}$  cycle threshold method. Values of 20% of the samples were repeated in separate experiments with 100% agreement. Results were expressed in arbitrary units (AUs) and fold change (FC). Genes evaluated and primer sequences are available in Supplementary Table 1.

#### Western blotting

Cells were harvested and total protein was extracted with RIPA-modified buffer containing protease inhibitors, followed by Lowry protein quantification. The cell lysates (20 µg) were subjected to 12% SDS-PAGE, and proteins were transferred to nitrocellulose membranes. The proteins reacted with rabbit anti-ERp29 monoclonal antibody (1:1000, ab175193, Abcam, Cambridge, UK) and rabbit anti-GAPDH monoclonal antibody (1:5000, sc25778, Santa Cruz, Dallas, TX, USA) overnight at 4°C. A horseradish peroxidaseconjugated goat anti-rabbit IgG antibody was used as the secondary antibody (1:10000, ab97051, Abcam). Chemiluminescent signals were visualized in the capture imaging system ImageQuant 350 (GE Healthcare, Danderyd, SWE) using SuperSignal West Pico Plus Chemiluminescent Substrate (Thermo Scientific), and signal intensity was analyzed by the ImageJ software (National Institutes of Health, Bethesda, MD, USA). The level of GAPDH was used as loading control and protein content normalization.

## **ER** stress

Briefly, 2 x  $10^5$  FaDu and FaDu-R cells were seeded in 6-well culture plates prior to treatment. Tunicamycin (TM, Sigma-Aldrich) was used to induce ER stress at a concentration of 20 µg/mL and 4-phenylbutyrate (4-PBA, Sigma-Aldrich) was used as an ER stress inhibitor at a concentration of 10 µM. The expression levels of *GRP78* and *GRP94* genes, indicators of ER stress, were evaluated by qPCR as described above.

### Cell cycle and proliferation

For cell cycle analysis, 5 x 10<sup>5</sup> FaDu, FaDu-CDDP and FaDu-R cells were seeded in 25 cm<sup>2</sup> culture flasks prior to transfection. Forty-eight hours after transfection, cells were fixed with ice-cold 70% ethanol for 1 h at 4°C and stained with 7-aminoactinomycin D (7-AAD) (Life Technologies), followed by flow cytometric analysis with NovoCyte 2060 (ACEA Biosciences). The fraction of cells in the G1 and S/G2 phases was determined from the DNA histograms using Novoexpress Cell Cycle Plot software (ACEA Biosciences).

For proliferation,  $1.5 \ge 10^3$  FaDu, FaDu-CDDP and FaDu-R cells were seeded in duplicate in 96-well culture plates and cultured for 72 h. Cell proliferation was quantified using CCK-8 (Sigma-Aldrich) reagent by measuring the optical density at 450 nm using the microplate reader spectrophotometer Epoch (BioTek).

#### Cell apoptosis and necrosis

Briefly, 5 x  $10^5$  FaDu, FaDu-CDDP and FaDu-R cells were seeded in 25 cm<sup>2</sup> culture flasks prior to transfection. Apoptosis was stimulated for 24 h with 600 µM of hydrogen peroxide for FaDu and FaDu-R cells, and with 5 µM of CDDP for FaDu-CDDP [39, 40]. Forty-eight hours after transfection, DNA was stained with Annexin V Apoptosis kit (Invitrogen), followed by flow cytometric analysis with NovoCyte 2060 (ACEA Biosciences), wherein the fractions of live cells, apoptotic cells (early and late stages), and necrotic cells were determined.

### Cell migration

Cell migration was assessed using the wound-healing assay. Briefly, 1 x 10<sup>5</sup> FaDu, FaDu-CDDP, FaDu-R, and LAU-2063 cells were seeded in 12-well culture plates prior to transfection. Twenty-four hours after transfection, monolayer cells were carefully wounded using sterilized pipette tips and the culture medium was replaced by DMEM supplemented with 2% FBS and 1% P/S. Wound cells were photographed immediately (0 h) and after being cultured for 24 h for LAU-2063 or 48 h for FaDu cells. Images were analyzed by the ImageJ software (National Institutes of Health).

#### ERP29 silencing effect across cell lines

After analyzing the cell cycle, proliferation, apoptosis, necrosis, and migration, we further evaluated whether *ERP29* silencing could exhibit a more prominent effect in any of the scenarios (CDDP-sensitive, treated, or resistant). We assessed only the functional assays that were significantly influenced by *ERP29* silencing (proliferation, necrosis, and migration) by evaluating the pattern of cells transfected with siRNA negative control and cells with *ERP29* silencing.

#### Immunofluorescence

E-cadherin immunofluorescence was performed on PFA-fixed spheroids. FaDu 3Dspheroids were permeabilized with 0.1% Triton X-100 and blocked in PBS 0.5% BSA containing 1% donkey serum for 1 hour at room temperature. Spheroids were incubated with rabbit anti-E-cadherin monoclonal antibody (1:500, 3195, Cell Signaling, Danvers, MA, USA) in PBS 0.2% BSA and 0.3% Triton-X at 4°C overnight and then with goat anti-rabbit Alexa Fluor 555 (1:500, A-21429, Life Technologies) in PBS 0.2% BSA and 0.3% Triton-X at room temperature for 2 hours. Sections were mounted in ProLong Gold antifade reagent with DAPI (P-36931, Life Technologies) and evaluated by fluorescence microscopy. The negative control FaDu 3D-spheroids' mean value was considered as 100% of E-cadherin immunoexpression. E-cadherin staining was used to corroborate the effect of *ERP29* silencing in cell migration via morphological changes.

#### Identification of genes modulated by ERP29

The plate array TaqMan Array Human Molecular Mechanisms of Cancer (assay n° 4418806, Applied Biosystems) was used to identify potential genes modulated by *ERP29* expression in FaDu cell line. The plate array comprises 92 genes enrolled in different

carcinogenesis pathways and four candidate endogenous control genes. FaDu with *ERP29* overexpression and FaDu with *ERP29* silencing cDNA samples were used and qPCR was carried out following the manufacturer's protocol. Gene IDs from the TaqMan plate array are listed in Supplementary Table 2. Among the four measured endogenous control genes, we chose *GAPDH* for gene expression normalization since it showed the most relatively constant expression between samples. Results were analyzed by DataAssist software (Thermo Scientific) and FaDu cDNA was used as calibrator sample. We choose those genes differentially expressed between cells with *ERP29* overexpression and *ERP29* silencing using a FC cutoff of  $\geq$  2. From 92 genes presented in the TaqMan plate array, we selected 13 genes involved in WNT, MAPK, and PI3K/AKT signaling pathways.

#### Validation of genes modulated by ERP29

To validate the plate array results, adenomatous polyposis coli (*APC*), transcription factor 3 (*TCF3*), guanine nucleotide exchange factor (*SOS1*), KRAS proto-oncogene (*KRAS*), *MAPK1*, Erb-B2 receptor tyrosine kinase 2 (*ERBB2*), SRC proto-oncogene (*SRC*), AKT serine/threonine kinase 1 (*AKT1*), integrin subunit alpha V (*ITGAV*), AP-1 transcription factor subunit (*JUN*), cyclin E1 (*CCNE1*), MDM2 proto-oncogene (*MDM2*), and caspase 9 (*CASP9*) were submitted to gene expression by qPCR using cDNA samples from FaDu, and additionally, FaDu-CDDP and FaDu-R with *ERP29* overexpression and *ERP29* silencing. Gene relative expression level was normalized to the reference housekeeping gene *GAPDH*.

#### Gene expression pattern across cell lines

To analyze if *ERP29* silencing could modify the expression pattern of the 13 identified genes across FaDu, FaDu-CDDP and FaDu-R cells, we compared gene expression levels by qPCR using cDNA samples from cells transfected with siRNA negative control and cells with *ERP29* silencing. Gene relative expression level was normalized to the reference housekeeping gene *GAPDH*.

#### ERP29 and miR-4421 interaction

Since miR-4421 modulated *ERP29* gene expression [36] and to analyze if miR-4421 inhibitor could revert *ERP29* silencing effects, we evaluate *ERP29* and miR-4421 inhibitor interaction.

We first transiently transfected FaDu and FaDu-R cells with 50 µM of synthetic sequence of miR-4421 inhibitor (assay ID MH22417, Invitrogen) using Lipofectamine 3000 (Invitrogen). A negative control miRNA sequence was also used (assay ID 4464058, Invitrogen). *ERP29* expression was analyzed by qPCR as described above.

We also performed qPCR to assess if miR-4421 inhibitor transfection could reflect on the expression of the identified genes modulated by *ERP29* silencing in FaDu, FaDu-CDDP and FaDu-R cells. We analyzed only the genes that were significantly modulated by *ERP29* silencing in each cell line (FaDu: *APC*, *TCF3*, *KRAS*, *MAPK1*, *ERBB2*, *SRC*, *AKT1*, *ITGAV*, *JUN*, *CCNE1*, *MDM2*, and *CASP9*; FaDu-CDDP: *MDM2* and *CASP9*; FaDu-R: *SOS1*, *KRAS*, *MAPK1*, *AKT1*, *ITGAV*, *JUN*, *CCNE1*, *MDM2*, and *CASP9*).

### Statistical analysis

Data sets were probed for normality using Shapiro-Wilk's test. Samples did assume a normal distribution; thus, we used *t* test to compare the groups. Tests were done using the SPSS 21.0 software (SPSS Incorporation, Chicago, IL, USA) and significance is two-sided and achieved when *p*-values were < 0.05.

#### Results

## Drug sensitivity assay

We established a CDDP-resistant FaDu cell line to investigate *ERP29* role in PSCC with CDDP resistance. FaDu-R cells were found to be significantly less sensitive to CDDP than parental FaDu cells (0.5  $\mu$ M CDDP treatment: FC: 0.7, *p*= 0.002 and 1.0  $\mu$ M CDDP treatment: FC: 0.8, *p*= 0.02) (Supplementary Fig. 1).

### ERP29 expression across cell lines

The basal expression of *ERP29* was assessed in FaDu, FaDu-CDDP, FaDu-R and LAU-2063 cells by qPCR. *ERP29* expression was decreased in FaDu-R cells when compared to FaDu (FC: 0.7, p= 0.01), FaDu-CDDP (FC: 0.7, p= 0.001) and LAU-2063 (FC: 0.3, p< 0.001) (Supplementary Fig. 2).

#### Induction of ERP29 overexpression and silencing

To evaluate how *ERP29* regulates behaviors of pharyngeal cancer cells, we first performed overexpression and silencing in FaDu and FaDu-R cells. Transient transfection efficiency was monitored by GFP detection and cells presented 37-48% of GFP positivity. qPCR and western blotting analysis confirmed the overexpression and silencing of *ERP29* gene and ERp29 protein, respectively, as shown in Supplementary Fig. 3. *ERP29* silencing was also performed in LAU-2063 cells that was confirmed by qPCR as shown in Supplementary Fig. 4.

In FaDu, cells with *ERP29* overexpression presented 278.4-fold (p= 0.004) and 109.2-fold (p= 0.03) increased *ERP29* gene expression and 4.7-fold (p< 0.001) and 1.7-fold (p= 0.03) increased ERp29 protein content than cells with *ERP29* silencing and *ERP29* overexpression control, respectively (Supplementary Fig. 3A). In addition, cells with *ERP29* silencing presented 0.2-fold decreased *ERP29* gene expression (p< 0.001) and 0.4-fold decreased ERp29 protein content (p< 0.001) than *ERP29* silencing control (Supplementary Fig. 3A). In FaDu-R, cells with *ERP29* overexpression presented 16.1-fold (p< 0.001) and 8.4-fold (p= 0.003) increased *ERP29* gene expression and 3.9-fold (p= 0.001) and 1.6-fold (p= 0.003) increased *ERP29* protein content than cells with *ERP29* silencing and *ERP29* overexpression control, respectively (Supplementary Fig. 3B). In addition, cells with *ERP29* silencing presented 0.4-fold decreased *ERP29* gene expression (p= 0.006) and 0.4-fold decreased *ERP29* protein content (p= 0.04) than *ERP29* silencing control (Supplementary Fig. 3B). In LAU-2063, cells with *ERP29* silencing presented 0.2-fold decreased *ERP29* silencing control (Supplementary Fig. 3B). In LAU-2063, cells with *ERP29* silencing presented 0.2-fold decreased *ERP29* silencing control (Supplementary Fig. 3B). In LAU-2063, cells with *ERP29* silencing presented 0.2-fold decreased *ERP29* silencing control (Supplementary Fig. 3B). In LAU-2063, cells with *ERP29* silencing presented 0.2-fold decreased *ERP29* gene expression (p< 0.001) than *ERP29* silencing control (Supplementary Fig. 4).

#### **ER** stress

FaDu and FaDu-R cells when treated with TM produced significantly increased expression of *ERP29* and ER stress representative genes *GRP78* and *GRP94* when compared to untreated cells (FaDu *ERP29* FC: 1.9, p= 0.003 (Supplementary Fig. 5A); *GRP78* FC: 27.4, p< 0.001 (Supplementary Fig. 5B); *GRP94* FC: 21.2, p< 0.001 (Supplementary Fig. 5C); FaDu-R *ERP29* FC: 2.0, p= 0.02 (Supplementary Fig. 5D); *GRP78* FC: 38.3, p< 0.001 (Supplementary Fig. 5E); *GRP94* FC: 25.5, p< 0.001) (Supplementary Fig. 5F). Moreover, 4-PBA treatment decreased *GRP78* and *GRP94* expression, alleviating ER stress, in TM-treated FaDu and FaDu-R cells (FaDu *GRP78* FC: 0.5, p= 0.03 (Supplementary Fig. 5B); *GRP94* FC: 0.2, p< 0.001 (Supplementary Fig. 5C); FaDu-R *GRP78* FC: 0.3, p= 0.01 (Supplementary Fig. 5E); *GRP94* FC: 0.3, p< 0.001 (Supplementary Fig. 5E)) when compared to TM treated cells. Simultaneously, *ERP29* expression was also decreased in FaDu cells (FC: 0.5, p= 0.002) (Supplementary Fig. 5A), but not in FaDu-R cells (p= 0.84) (Supplementary Fig. 5D).

To investigate whether *ERP29* silencing influences ER stress, *ERP29* silenced FaDu and FaDu-R cells were treated with TM. *GRP78* and *GRP94* expression were decreased when compared to TM treated cells with *ERP29* expression (FaDu *GRP78* FC: 0.1, p< 0.001 (Supplementary Fig. 5B); *GRP94* FC: 0.2, p< 0.001 (Supplementary Fig. 5C); FaDu-R *GRP78* FC: 0.2, p< 0.001 (Supplementary Fig. 5E); *GRP94* FC: 0.3, p= 0.02) (Supplementary Fig. 5F).

### Cell cycle and proliferation

*ERP29* overexpression or silencing did not affect cell cycle phases (details can be found in Supplementary Table 3) nor proliferation in FaDu and FaDu-R cells (Table 1). In FaDu-CDDP cells, *ERP29* silencing did not modulate cell cycle phases (Supplementary Table 3) but increased cell proliferation when compared to *ERP29* overexpression (107.9%  $\pm$  3.5% vs 100.5%  $\pm$  2.8%, p= 0.04) and negative control (107.9%  $\pm$  3.5% vs 93.6%  $\pm$  3.1%, p= 0.006) (Table 1).

#### Cell apoptosis and necrosis

*ERP29* silencing did not affect cell apoptosis but decreased cell necrosis (Table 2). In FaDu cells, *ERP29* silencing decreased necrosis when compared to *ERP29* overexpression  $(0.6\% \pm 0.1\% vs 1.3\% \pm 0.2\%, p < 0.001)$ . Besides, *ERP29* overexpression increased necrosis when compared to negative control  $(1.3\% \pm 0.2\% vs 0.5\% \pm 0.2\%, p = 0.003)$ . In FaDu-CDDP cells, *ERP29* silencing decreased necrosis when compared to *ERP29* overexpression  $(0.2\% \pm 0.05\% vs 0.9\% \pm 0.4\%, p = 0.02)$  and negative control  $(0.2\% \pm 0.05\% vs 0.4\% \pm 0.2\%, p = 0.04)$  (Table 2). In FaDu-R cells, *ERP29* silencing decreased necrosis when compared to *ERP29* overexpression  $(0.5\% \pm 0.1\% vs 1.1\% \pm 0.4\%, p = 0.02)$  and negative control  $(0.5\% \pm 0.1\% vs 0.7\% \pm 0.2\%, p = 0.03)$ . Besides, *ERP29* overexpression increased necrosis when compared to negative control  $(1.1\% \pm 0.4\% vs 0.5\% \pm 0.1\%, p = 0.04)$  (Table 2).

### **Cell migration**

*ERP29* silencing exhibited a significant increase in FaDu, FaDu-CDDP, FaDu-R and LAU-2063 migration rate. In FaDu cells, *ERP29* silencing decreased wound surface area when compared to *ERP29* overexpression (53.5%  $\pm$  5.0% vs 82.7%  $\pm$  8.9%, p< 0.001) and negative control (53.5%  $\pm$  5.0% vs 60.8%  $\pm$  3.8%, p= 0.04) (Fig. 1A). In FaDu-CDDP cells, *ERP29* silencing decreased wound surface area when compared to *ERP29* overexpression (53.1%  $\pm$  4.0% vs 72.9%  $\pm$  7.3%, p= 0.02) and negative control (53.1%  $\pm$  4.0% vs 62.6%  $\pm$  3.8%, p= 0.02) (Fig. 1B). In FaDu-R cells, *ERP29* silencing decreased wound surface area when compared to *ERP29* overexpression (68.2%  $\pm$  9.1% vs 90.3%  $\pm$  5.0%, p= 0.01). Besides, *ERP29* overexpression increased wound surface area when compared to negative control (90.3%  $\pm$  5.0% vs 71.5%  $\pm$  13.0%, p= 0.04) (Fig. 1C). In LAU-2063 cells, *ERP29* silencing decreased wound surface area when compared to negative control (50.7%  $\pm$  12.2% vs 73.7%  $\pm$  13.4%, p= 0.04) (Fig. 1D).

## ERP29 silencing effect across cell lines

We observed a different pattern in proliferation and necrosis rates between FaDu, FaDu-CDDP, and FaDu-R cells when *ERP29* was silenced.

In cell proliferation assay, we observed that the proliferation rate was lower in FaDu-CDDP transfected with negative control when compared with FaDu (93.6%  $\pm$  3.1% vs 107.9%  $\pm$  1.0%, p= 0.002). However, in *ERP29* silenced cells, the proliferation rate was similar between FaDu, FaDu-CDDP, and FaDu-R (Supplementary Fig. 6A).

In necrosis assay, we observed that the necrosis rate was similar between FaDu, FaDu-CDDP, and FaDu-R cells transfected with negative control. However, in *ERP29* silenced cells, the necrosis rate was lower in FaDu-CDDP when compared with FaDu and FaDu-R cells ( $0.2\% \pm 0.05\% vs \ 0.6\% \pm 0.1\%$ , p < 0.001 and  $0.2\% \pm 0.05\% vs \ 0.5\% \pm 0.1\%$ , p = 0.002) (Supplementary Fig. 6B).

In migration assay, we didn't observe any differences in FaDu, FaDu-CDDP, FaDu-R, and LAU-2063 cells transfected with negative control or with *ERP29* silencing (Supplementary Fig. 6C).

### 3D cell culture and immunofluorescence

FaDu 3D-spheroids were kept in culture for six days to allow the development of spheroids before immunofluorescence staining (Supplementary Fig. 7). FaDu 3D-spheroids

with *ERP29* silencing decreased E-cadherin immunoexpression levels when compared to negative control transfected cells (54.2%  $\pm$  13.4% vs 100.0%  $\pm$  25.0%; *p*= 0.04) (Fig. 2).

### Identification and validation of genes modulated by ERP29

From 92 genes presented in the TaqMan plate array, we selected 13 genes involved in WNT, MAPK, and PI3K/AKT signaling pathways: *APC*, *TCF3*; *SOS1*, *KRAS*, *MAPK1*; *ERBB2*, *SRC*, *AKT1*, *ITGAV*, *JUN*, *CCNE1*, *MDM2*, and *CASP9*, respectively (Supplementary Fig. 8). The identified genes were validated by qPCR (Fig. 3).

We found that, in FaDu cells, *ERP29* silencing increased *APC* (FC: 5.9, p= 0.04), *TCF3* (FC: 8.4, p= 0.04) (WNT pathway); *KRAS* (FC: 2.8, p= 0.01), *MAPK1* (FC: 2.4, p= 0.03) (MAPK pathway); *ERBB2* (FC: 3.7, p= 0.01), *SRC* (FC: 6.4, p= 0.01), *AKT1* (FC: 17.4, p= 0.004), *ITGAV* (FC: 6.7, p= 0.01), *JUN* (FC: 29.5, p= 0.01), *CCNE1* (FC: 2.0, p= 0.002), and *MDM2* (FC: 6.5, p= 0.002) (PI3K/AKT pathway); and decreased *CASP9* (FC: 0.5, p= 0.03) expression when compared to *ERP29* overexpression (Fig. 3A). In FaDu-CDDP cells, *ERP29* silencing decreased *MDM2* (FC: 0.7, p= 0.02) and *CASP9* (FC: 0.5, p= 0.02) expression when compared to *ERP29* overexpression (Fig. 3B). In FaDu-R, *ERP29* silencing increased *SOS1* (FC: 2.2, p= 0.04), *MAPK1* (FC: 2.1, p= 0.002); *AKT1* (FC: 2.2, p= 0.04), *ITGAV* (FC: 1.9, p= 0.04), and *CCNE1* (FC: 1.4, p= 0.02); and decreased *KRAS* (FC: 0.1, p< 0.001), *JUN* (FC: 0.5, p= 0.03), *MDM2* (FC: 0.4, p= 0.02), and *CASP9* (FC: 0.3, p< 0.001) expression when compared to *ERP29* overexpression (Fig. 3C).

#### Gene expression pattern across cell lines

We observed a different pattern of gene expression among the selected genes between FaDu, FaDu-CDDP, and FaDu-R cells when *ERP29* was silenced.

The expression levels of *APC*, *TCF3* (WNT pathway), *ITGAV*, and *CCNE1* (PI3K/AKT pathway) were similar between the three cell lines transfected with negative control, and the expression levels of *KRAS* (MAPK pathway) and *AKT1* (PI3K/AKT pathway) were similar between FaDu and FaDu-CDDP cells transfected with negative control. However, in *ERP29* silenced cells, the expression levels of the referred genes were decreased in FaDu-CDDP when compared with FaDu and/or FaDu-R (*APC* FC: 0.5, p= 0.01; *TCF3* FC: 0.2, p= 0.03; *ITGAV* FC: 0.3, p= 0.02 and FC: 0.4, p= 0.01; *CCNE1* FC: 0.5, p< 0.001 and FC: 0.3, p< 0.001 and FC: 0.3, p= 0.001 and FC: 0.2, p= 0.01; and *AKT1* FC: 0.5, p= 0.04)

(Supplementary Fig. 9). Likewise, the expression levels of *SOS1* (MAPK pathway), *SRC*, *JUN*, and *MDM2* (PI3K/AKT pathway) were found to be increased in FaDu-CDDP transfected with negative control when compared with FaDu and FaDu-R. However, in *ERP29* silenced cells, the expression levels of the referred genes were similar or decreased in comparison with FaDu and/or FaDu-R (*SOS1* FC: 0.4, p= 0.14 and FC: 0.5, p= 0.07; *SRC* FC: 0.7, p= 0.47 and FC: 0.6, p= 0.23; *JUN* FC: 0.2, p= 0.03; and *MDM2* FC: 0.4, p= 0.02) (Supplementary Fig. 9). Moreover, we found that *ERP29* silenced FaDu-R cells presented a decreased expression level of *JUN* (FC: 0.3, p= 0.03) and an increased expression and *CCNE1* (FC: 1.4, p= 0.01) when compared with *ERP29* silenced FaDu cells, what was not seen in FaDu and FaDu-R cells transfected with negative control (Supplementary Fig. 9).

We did not observe a significant difference in *MAPK1* (MAPK pathway), *ERBB2* and *CASP9* (PI3K/AKT pathway) expression pattern across cell lines (Supplementary Fig. 9).

## ERP29 and miR-4421 interaction

The transfection of miR-4421 inhibitor in FaDu and FaDu-R cells increased *ERP29* expression when compared with miRNA negative control (FC: 1.9, p= 0.03 and FC: 1.9, p= 0.02, respectively) (Supplementary Fig. 10).

We further evaluate if miR-4421 inhibitor transfection could reflect on the expression of the identified genes modulated by *ERP29* silencing. We found that, in FaDu cells, miR-4421 inhibitor decreased *MAPK1* (FC: 0.3, p= 0.02 and FC: 0.6, p= 0.03) (MAPK pathway), *AKT1* (FC: 0.02, p< 0.001 and FC: 0.1, p= 0.02) and *JUN* (FC: 0.01, p= 0.01 and FC: 0.1, p= 0.02) (PI3K/AKT pathway) expression when compared with *ERP29* silencing and miRNA negative control, respectively (Fig. 4). In FaDu-R cells, miR-4421 inhibitor decreased *SOS1* (FC: 0.1, p< 0.001 and FC: 0.2, p= 0.03), *MAPK1* (FC: 0.3, p< 0.001 and FC: 0.4, p= 0.01) (MAPK pathway), *AKT1* (FC: 0.04, p< 0.001 and FC: 0.2, p= 0.04) and *ITGAV* (FC: 0.08, p< 0.001 and FC: 0.2, p= 0.04) (PI3K/AKT pathway) expression when compared with *ERP29* silencing and miRNA negative control, respectively (Fig. 4). Details and other gene comparisons are presented in Supplementary Table 4.

### Discussion

We investigated whether *ERP29* influences PSCC behaviors under different scenarios: tumor cells before CDDP treatment (FaDu and LAU-2063), during CDDP treatment (FaDu-

CDDP), and tumor cells with CDDP-acquired resistance (FaDu-R). CDDP is widely used in patients' treatment, and acquired resistance is a major contributor to therapy failure and low survival rates [8, 9].

Initially, we assessed *ERP29* basal expression and we found that FaDu-R presented a decreased expression of *ERP29* compared to the other cells (FaDu, FaDu-CDDP, and LAU-2063), highlighting a possible relationship between *ERP29* silencing and CDDP resistance [9]. We also evaluate the *ERP29* role in ER stress and we found that *ERP29* silencing decreased ER stress in FaDu and FaDu-R cells. Decreased ER stress in head and neck cancer (HNC), including PSCC, has previously been associated with increased cell proliferation and decreased apoptosis [14]. Low expression of the ER stress marker *GRP78* was associated with poor overall survival and progression-free survival in patients with advanced HNC (III or IV stages) [41]. Moreover, *ERP29* silencing was associated with decreased ER stress in cervical [42] and colorectal [32] cancer. Thus, our result highlights the importance of *ERP29* in PSCC, justifying the following functional assays.

*ERP29* silencing did not influence cell cycle phases or proliferation in FaDu and FaDu-R cells. In FaDu-CDDP, *ERP29* silencing did not influence cell cycle phases but slightly enhanced cell proliferation. *ERP29* silencing was associated with increased breast [20, 27], gastric [22], and hepatic [31] tumor proliferation and decreased colorectal [43] and *TP53* mutated lung [35] tumor proliferation. On the other hand, *ERP29* expression did not modulate the lung [44] and gastric [29] cancer proliferation in other studies. These results highlight the tissue-specific role of *ERP29* [19]. In HNC, including PSCC, our study is the first to evaluate *ERP29* modulation in cell cycle phases and proliferation. When we observed the cell line pattern, we particularly noticed that cells with *ERP29* silencing during CDDP treatment seemed able to neutralize the damage caused by CDDP and equalize the proliferation rate of cells that have not undergone treatment (FaDu and FaDu-R). Thus, especially during CDDP treatment, *ERP29* silencing could facilitate tumor proliferation, potentially increasing the chances of chemoresistance and therapy failure.

*ERP29* silencing did not influence apoptosis in FaDu, FaDu-CDDP, and FaDu-R cells. In curcumin-treated breast cancer cells, *ERP29* silencing was associated with decreased apoptosis [45]. However, in doxorubicin-treated breast cancer cells [33], radiotherapy-treated nasopharynx cancer cells [46], and non-treated colorectal cancer cells [43], *ERP29* silencing was capable of increasing apoptosis. To the best of our knowledge, no report in the literature focuses on the *ERP29* role in apoptosis mediated by CDDP treatment. On the other hand, and in compliance with our study, *ERP29* expression did not influence apoptosis in non-treated breast cancer cells [27]. These results highlight the tissue-specific role of *ERP29* and its modulation depending on the therapy used [19]. However, *ERP29* silencing decreased the necrosis rate in FaDu, FaDu-CDDP, and FaDu-R cells. To the best of our knowledge, our study is the first to associate the *ERP29* gene and necrosis. This association was demonstrated only in the patent application titled "*Monoclonal Antibody Against Necrosis Marker Erp29 And Use Thereof*" in which *ERP29* overexpression was seen in necrotic tumor cells rather than in non-necrotic tumor cells [47]. When we observed the cell line pattern, we particularly noticed that cells with *ERP29* silencing during CDDP treatment had the lowest necrosis rate compared to FaDu and FaDu-R. Thus, our results suggest that *ERP29* silencing could protect tumor cells from necrosis-induced death, favoring tumor progression in all scenarios (including tumor cells before and during CDDP treatment, and those with CDDP resistance), but especially during CDDP treatment.

*ERP29* silencing increased FaDu, FaDu-CDDP, FaDu-R, and LAU-2063 cell migration. In lung [35, 44] and colorectal [32] cancer, *ERP29* silencing was associated with decreased tumor cell migration. On the other hand, and in compliance with our study, *ERP29* silencing increased breast [27], gastric [22, 29], hepatic [31], and colorectal [48] cancer cell migration, especially by promoting epithelial-mesenchymal transition (EMT). In HNC, including PSCC, our study is the first to associate the *ERP29* gene and cell migration. Additionally, we found that *ERP29* silencing decreased E-cadherin immunoexpression in FaDu 3D-spheroids. Loss of E-cadherin is related to EMT, and it is essential for PSCC cell invasion and migration [49]. In breast cancer, *ERP29* silencing was also associated with decreased E-cadherin expression and EMT activation [27]. When we observed the cell line pattern, we noticed that *ERP29* silencing influenced migration in all scenarios (including tumor cells before and during CDDP treatment, and those with CDDP resistance) similarly. Thus, our results highlight the importance of *ERP29* silencing in PSCC cell migration, which could contribute to tumor progression and metastasis in patients or during CDDP treatment, including those with CDDP-resistant tumors.

Finally, we assessed the genes modulated by *ERP29* expression. In FaDu cells, we found that *ERP29* silencing increased the expression of *APC*, *TCF3* (enrolled in WNT signaling), *KRAS*, *MAPK1* (enrolled in MAPK signaling), *ERBB2*, *SRC*, *AKT1*, *ITGAV*,

JUN, CCNE1, and MDM2, and decreased CASP9 expression (enrolled in PI3K/AKT signaling). Aberrant activation of WNT, MAPK, and PI3K/AKT pathways are commonly found in PSCC and are associated with increased cell proliferation, differentiation, and migration [10-12]. Increased APC expression was an unexpected event, once the APC protein is a WNT signaling inhibitor [10]. However, APC overexpression was previously associated with disordered cell migration of murine epithelial cells [50] and poor prognosis in patients with advanced gastric cancer [51]. Moreover, APC overexpression was observed in oral carcinoma, increasing proliferation and differentiation [52]. Additional studies must understand APC overexpression in PSCC and its relationship with ERP29. The association of ERP29 silencing and MAPK1 overexpression was previously reported in the breast cancer cell line, possibly facilitating tumor cell invasion and metastasis [27]. Despite the increased expression levels of genes involved in cell proliferation, we could not detect ERP29 influence in FaDu proliferation in our study. However, we believe that ERP29 silencing could modulate PSCC cell migration by activation of WNT, MAPK, and PI3K/AKT signaling pathways. Moreover, we observed that *ERP29* silencing decreased the expression of CASP9 in FaDu cells. CASP9 role in promoting apoptosis is well-known in PSCC [53]. However, CASP9 also contributes to the necroptosis process, an alternative and programmed form of cell death that mimics features of apoptosis and necrosis [54]. Unfortunately, we could not distinguish between necrotic and necroptotic events in our study. Thus, we suggest that ERP29 silencing could decrease necrotic/necroptotic events by decreasing CASP9 expression.

In FaDu-CDDP cells, we observed that *ERP29* silencing decreased the expression of *MDM2*. MDM2 protein interacts with p53 protein and silence its tumor suppressor effects [55]. On the other hand, CDDP can directly bind to MDM2 protein, preventing p53 degradation [55]. Most tumor cells exhibit p53 mutations, including FaDu, that present p53(R248L) mutation. These mutations not only lead to a loss of tumor suppressor ability, but they can also increase tumor progression [56]. Thus, we believe that, during CDDP treatment, *ERP29* silencing could potentialize p53(R248L) oncogenic function by decreasing the *MDM2* expression, influencing cell proliferation and migration. We also observed that *ERP29* silencing decreased the expression of *CASP9* in FaDu-CDDP cells. As well as in FaDu cells, we suggest that *ERP29* silencing could decrease necrotic/necroptotic events by decreasing *CASP9* expression in FaDu-CDDP cells.

In FaDu-R cells, we observed that *ERP29* silencing increased the expression of *SOS1*, MAPK1, AKT1, ITGAV, and CCNE1. The overexpression of SOS1, MAPK1, AKT1, and ITGAV genes was previously associated with increased HNC migration [57, 58]. Thus, we believe that ERP29 silencing could increase FaDu-R cell migration by SOS1, MAPK1, AKT1, and ITGAV overexpression, and not necessarily by complete activation of the MAPK and PI3K/AKT pathways. The CCNE1 gene participates in PSCC cell cycle progression and proliferation [59]. Despite the increased expression levels of CCNE1, we could not detect ERP29 influence in FaDu-R cell proliferation in our study. We also observed that ERP29 silencing decreased the expression of CASP9, enrolled in the necroptosis process [54]. As well as in FaDu and FaDu-CDDP cells, we suggest that ERP29 silencing could decrease necrotic/necroptotic events by decreasing CASP9 expression in FaDu-R cells. Finally, we observed that ERP29 silencing decreased the expression of KRAS, JUN, and MDM2. In contradiction to what is expected for MAPK and PI3K/AKT pathways, in CDDP-resistant cells, the activation of those pathways may benefit tumor cell death, including decreased cell proliferation and increased apoptosis process [60]. In particular, JUN contributes to apoptosis in CDDP-resistant cells [60]. The exact role of KRAS in this context is unknown. However, we believe that the decreased expression of KRAS and JUN may increase FaDu-R cell survival [60]. In concern to the decreased expression of MDM2, as well as in FaDu-CDDP, we believe that ERP29 silencing could potentialize p53(R248L) oncogenic function by decreasing the MDM2 expression, influencing cell proliferation and migration. Thus, we suggest that ERP29 silencing could modulate KRAS, JUN, and MDM2 expression to promote FaDu-R cell survival.

We evaluate whether *ERP29* silencing could modify the WNT, MAPK, and PI3K/AKT genes' expression patterns in FaDu, FaDu-CDDP, and FaDu-R. We observed a different pattern, especially in FaDu-CDDP for *APC*, *TCF3*, *SOS1*, *KRAS*, *SRC*, *AKT1*, *ITGAV*, *JUN*, *CCNE1*, and *MDM2* genes. Among them, *KRAS* [61, 62], *SRC* [40, 63], *AKT1* [64, 65], *JUN* [66, 67], and *MDM2* [68, 69] genes were previously associated with CDDP treatment modulation in HNC, including PSCC. *APC* gene was associated with CDDP treatment modulation in the breast [70] and lung [71] cancer; *TCF3* gene in ovarian cancer [72]; *SOS1* gene in hepatic cancer [73] and glioblastoma [74]; *ITGAV* gene in osteosarcoma [75], and *CCNE1* gene in bladder [76] and gastric [77] cancer. Although further experiments are necessary to comprehensively evaluate this association, our study found that *ERP29* silencing modulated cell proliferation exclusively in FaDu during CDDP treatment. This finding may be explained by the modification of genes' expression patterns that could ensure tumor survival. Our study is the first to associate the *ERP29* gene with the modulation of CDDP treatment in PSCC, which has significant implications not only for pharynx carcinogenesis but also for all cancers treated with CDDP.

As we previously reported, miR-4421 interacts with the *ERP29* gene, decreasing its expression and protein production [36]. Once we found that *ERP29* silencing influenced PSCC malignant behaviors in this study, we further evaluated the potential therapeutic role of the miR-4421 inhibitor. We found that the miR-4421 inhibitor increased *ERP29* expression in FaDu and FaDu-R cells indeed and decreased *MAPK1*, *AKT1*, and *JUN* expression in FaDu, and *SOS1*, *MAPK1*, *AKT1*, and *ITGAV* expression in FaDu-R cells, reverting *ERP29* silencing modulation on those genes. The therapeutic potential of the miR-4421 inhibitor needs to be further explored in other functional assays. In the literature, miR-4421 inhibition has not been explore; however, miR-4421 was found to be the upregulated in esophageal carcinoma [78] and osteosarcoma [79].

At present, no registered clinical trials involve the use of *ERP29* or miR-4421. However, therapies based on miRNA inhibitors (antagomiRs) have improved over the last few years [80]. For example, Cobomarsen (miRagen Therapeutics, Waltham, MA, USA), a miR-155 inhibitor, was undergoing a clinical trial to treat cutaneous T-cell lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia patients [81]. The therapy restores the expression of WEE1 G2 checkpoint kinase (*WEE1*) and cut like homeobox 1 (*CUX1*) genes, which could lead to decreased tumor cell proliferation and increased apoptosis [81]. Thus, a miR-4421 inhibitor therapy should be further explored and we believe that it could beneficiate PSCC patients, regardless of CDDP sensitivity or resistance.

We are aware that our study has several limitations. Our data should be confirmed in other cell lines, including non-immortalized PSCC cells, and additional studies of protein interaction are also required. Besides, our results could benefit from a different methodology for a stable *ERP29* gene modulation that would allow to study *ERP29* influence in cellular mechanisms for a more extended period, not just a few days after transfection as we performed a transient modification. This way our results, especially proliferation and necrosis rate, would be enriched. Additionally, the exact biological

mechanisms underlying the observed association between *ERP29* and WNT, MAPK, and PI3K/AKT pathways require further elucidation. However, we believe that our study is a necessary starting point to further clarify *ERP29* role in PSCC.

In summary, we identified the potential role of *ERP29* silencing in PSCC, especially in decreasing cell necrosis and enhancing cell migration in CDDP-sensitive, treated, and resistant cells by modulating genes enrolled in WNT, MAPK, and PI3K/AKT signaling pathways. Our study contributes to the understanding of PSCC progression and CDDP resistance, and we hope that our data could assist in the development of target therapy for PSCC patients based on ensuring *ERP29* expression.

Furthermore, our study contributes to a broad field of study, which is the understanding of CDDP treatment modulation and resistance. Besides HNC, CDDP is used to treat several types of cancers, as lymphoma, melanoma, bladder, lung, testicular, ovarian, and cervical cancers, both in developed and undeveloped countries, despite the advancements in new treatments such as immunotherapy [82]. Thus, our study contributes, although preliminarily, to the effort to understand and improve anticancer drugs for better treatment of patients.

### **Declaration of competing interest**

The authors declare no conflict of interest.

## Acknowledgements

This study received support from the National Council for Scientific and Technological Development (CNPq) (process n° 140019/2020-0 and n° 307944/2022-0).

## Data availability

The data generated in this study are available upon request from the corresponding author.

# References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-49.

[2] Mendenhall W, Werning J, Pfister D. Treatment of head and neck cancers. In: V.T. De Vita, T.S. Lawrence, R. SA editors. Cancer: Principles & Practice of Oncology, 9 edn. (Philadelphia: Lippincott Williams & Wilkins, 2011), pp. 729-80.

[3] Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010;2:15.

[4] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11(1):9-22.

[5] Lourenço GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CSP. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol 2011;32(6):1209-15.

[6] Costa EF, Santos ES, Liutti VT, Leal F, Santos VC, Rinck-Junior JA, et al. Association between polymorphisms in genes related to DNA base-excision repair with risk and prognosis of oropharyngeal squamous cell carcinoma. J Cancer Res Clin Oncol 2016;142(9):1917-26.

[7] Carron J, Torricelli C, Silva JK, Liu Y, Pellegrino R, Lima CSP, et al. Association of Inherited Copy Number Variation in ADAM3A and ADAM5 Pseudogenes with Oropharynx Cancer Risk and Outcome. Genes (Basel) 2022;13(12):2408.

[8] Philouze P, Péron J, Poupart M, Pujo K, Buiret G, Céruse P. Salvage surgery for oropharyngeal squamous cell carcinomas: A retrospective study from 2005 to 2013. Head Neck 2017;39(9):1744-50.

[9] Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012;64(3):706-21.

[10] Alamoud KA, Kukuruzinska MA. Emerging Insights into Wnt/ $\beta$ -catenin Signaling in Head and Neck Cancer. J Dent Res 2018;97(6):665-73.

[11] Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009;45(4-5):324-34.

[12] Vander Broek R, Mohan S, Eytan DF, Chen Z, Van Waes C. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. Oral Dis 2015;21(7):815-25.

[13] Jiang Z, Zhang G, Huang L, Yuan Y, Wu C, Li Y. Transmissible Endoplasmic Reticulum Stress: A Novel Perspective on Tumor Immunity. Front Cell Dev Biol 2020;**8**:846.

[14] Rayess HM, Xi Y, Garshott DM, Brownell AL, Yoo GH, Callaghan MU, et al. Benzethonium chloride activates ER stress and reduces proliferation in HNSCC. Oral Oncol 2018;76:27-33.

[15] Gu C, Zhang Y, Chen D, Liu H, Mi K. Tunicamycin-induced endoplasmic reticulum stress inhibits chemoresistance of FaDu hypopharyngeal carcinoma cells in 3D collagen I cultures and in vivo. Exp Cell Res 2021;405(2):112725.

[16] Huang ZH, Qiao J, Feng YY, Qiu MT, Cheng T, Wang J, et al. Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma

and promotes endoplasmic reticulum stress-induced cell apoptosis. Cell Cycle 2020;19(13):1576-89.

[17] Brecker M, Khakhina S, Schubert TJ, Thompson Z, Rubenstein RC. The Probable, Possible, and Novel Functions of ERp29. Front Physiol 2020;**11**:574339.

[18] Sargsyan E, Baryshev M, Szekely L, Sharipo A, Mkrtchian S. Identification of ERp29, an endoplasmic reticulum lumenal protein, as a new member of the thyroglobulin folding complex. J Biol Chem 2002;277(19):17009-15.

[19] Chen S, Zhang D. Friend or foe: Endoplasmic reticulum protein 29 (ERp29) in epithelial cancer. FEBS Open Bio 2015;5:91-8.

[20] Bambang IF, Lee YK, Richardson DR, Zhang D. Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells. Oncogene 2013;32(10):1240-51.

[21] Shnyder SD, Mangum JE, Hubbard MJ. Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer. J Proteome Res 2008;7(8):3364-72.

[22] Wu J, Yang Y, Gao S, Jiang H, Wang WQ, Xiao Y, et al. ERp29 inhibits tumorigenicity by suppressing epithelial mesenchymal transition in gastric cancer. Oncotarget 2017;8(45):78757-66.

[23] Myung JK, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci 2004;2(1):8.

[24] Feng Y, Tian ZM, Wan MX, Zheng XB. Protein profile of human hepatocarcinoma cell line SMMC-7721: identification and functional analysis. World J Gastroenterol 2007;13(18):2608-14.

[25] Banjerdpongchai R, Kongtawelert P, Khantamat O, Srisomsap C, Chokchaichamnankit D, Subhasitanont P, et al. Mitochondrial and endoplasmic reticulum stress pathways cooperate in zearalenone-induced apoptosis of human leukemic cells. J Hematol Oncol 2010;3:50.

[26] Deng YJ, Tang N, Liu C, Zhang JY, An SL, Peng YL, et al. CLIC4, ERp29, and Smac/DIABLO derived from metastatic cancer stem-like cells stratify prognostic risks of colorectal cancer. Clin Cancer Res 2014;20(14):3809-17.

[27] Bambang IF, Xu S, Zhou J, Salto-Tellez M, Sethi SK, Zhang D. Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells. Lab Invest 2009;89(11):1229-42.

[28] Gao D, Bambang IF, Putti TC, Lee YK, Richardson DR, Zhang D. ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK. Lab Invest 2012;92(2):200-13.

[29] Ye J, Huang J, Xu J, Huang Q, Wang J, Zhong W, et al. ERp29 controls invasion and metastasis of gastric carcinoma by inhibition of epithelial-mesenchymal transition via PI3K/Aktsignaling pathway. BMC Cancer 2017;17(1):626.

[30] Zhang K, Yao H, Yang Z, Li D, Yang L, Zou Q, et al. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas. Clin Transl Oncol 2016;18(4):352-9.

[31] Li X, Cheng T, He Y, Zhou S, Wang Y, Zhang K, et al. High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway. Life Sci 2019;232:116602.

[32] Guo L, Ma L, Liu C, Lei Y, Tang N, Huang Y, et al. ERp29 counteracts the suppression of malignancy mediated by endoplasmic reticulum stress and promotes the metastasis of colorectal cancer. Oncol Rep 2019;41(3):1603-15.

[33] Zhang D, Putti TC. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. Exp Cell Res 2010;316(20):3522-31.

[34] Qi L, Wu P, Zhang X, Qiu Y, Jiang W, Huang D, et al. Inhibiting ERp29 expression enhances radiosensitivity in human nasopharyngeal carcinoma cell lines. Med Oncol 2012;29(2):721-8.

[35] Zhang Y, Hu Y, Wang JL, Yao H, Wang H, Liang L, et al. Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp. Oncogene 2017;36(39):5473-83.

[36] Carron J, Costa APD, Rinck-Junior JA, Mariano FV, de Sá Carvalho B, Lima CSP, et al. Role of a genetic variation in the microRNA-4421 binding site of ERP29 regarding risk of oropharynx cancer and prognosis. Sci Rep 2020;10(1):17039.

[37] Naik PP, Mukhopadhyay S, Panda PK, Sinha N, Das CK, Mishra R, et al. Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma. Cell Prolif 2018;51(1):e12411.

[38] Chen S, Zhang Y, Zhang D. Endoplasmic reticulum protein 29 (ERp29) confers radioresistance through the DNA repair gene, O(6)-methylguanine DNA-methyltransferase, in breast cancer cells. Sci Rep 2015;5:14723.

[39] Lee E, Han AR, Nam B, Kim YR, Jin CH, Kim JB, et al. Moscatilin Induces Apoptosis in Human Head and Neck Squamous Cell Carcinoma Cells via JNK Signaling Pathway. Molecules 2020;25(4):901.

[40] Yang Z, Liao J, Carter-Cooper BA, Lapidus RG, Cullen KJ, Dan H. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway. BMC Cancer 2019;19(1):485.

[41] Kaira K, Toyoda M, Shimizu A, Imai H, Sakakura K, Nikkuni O, et al. Prognostic significance of GRP78/BiP expression in patients with Stage III/IV hypopharyngeal squamous cell carcinoma. Neoplasma 2016;63(3):477-83.

[42] Feng L, Zhang D, Fan C, Ma C, Yang W, Meng Y, et al. ER stress-mediated apoptosis induced by celastrol in cancer cells and important role of glycogen synthase kinase- $3\beta$  in the signal network. Cell Death Dis 2013;4:e715.

[43] Huang J, Jing M, Chen X, Gao Y, Hua H, Pan C, et al. ERp29 forms a feedback regulation loop with microRNA-135a-5p and promotes progression of colorectal cancer. Cell Death Dis 2021;12(11):965.

[44] Ye W, Zhang R, Hu Y, Xu X, Ying K. Increased expression of endoplasmic reticulum protein 29 in lung adenocarcinoma is associated with chemosensitivity to gemcitabine. Anticancer Drugs 2015;26(6):612-9.

[45] Fang HY, Chen SB, Guo DJ, Pan SY, Yu ZL. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine 2011;18(8-9):697-703.

[46] Wu P, Zhang H, Qi L, Tang Q, Tang Y, Xie Z, et al. Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncol Rep 2012;27(4):987-94.

[47] Sugano S, Kanzaki Y, Saga T, Tsuji A, inventors; FUJIFILM Corporation, assignee. Monoclonal Antibody Against Necrosis Marker Erp29 And Use Thereof. JP2013.

[48] Cheng KC, Kuo HC, Hsieh MC, Huang CY, Teng CC, Tung SY, et al. Identification of Two Novel CIL-102 Upregulations of ERP29 and FUMH to Inhibit the Migration and Invasiveness of Colorectal Cancer Cells by Using the Proteomic Approach. Biomolecules. 2021;11(9):1280.

[49] Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol 2013;49(4):287-92.

[50] Wong MH, Hermiston ML, Syder AJ, Gordon JI. Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium. Proc Natl Acad Sci USA 1996;93(18):9588-93.

[51] Du WB, Lin CH, Chen WB. High expression of APC is an unfavorable prognostic biomarker in T4 gastric cancer patients. World J Gastroenterol 2019;25(31):4452-67.

[52] Tsuchiya R, Yamamoto G, Nagoshi Y, Aida T, Irie T, Tachikawa T. Expression of adenomatous polyposis coli (APC) in tumorigenesis of human oral squamous cell carcinoma. Oral Oncol 2004;40(9):932-40.

[53] Kuwahara D, Tsutsumi K, Oyake D, Ohta T, Nishikawa H, Koizuka I. Inhibition of caspase-9 activity and Apaf-1 expression in cisplatin-resistant head and neck squamous cell carcinoma cells. Auris Nasus Larynx 2003;30 Suppl:S85-8.

[54] Avrutsky MI, Troy CM. Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease. Front Pharmacol 2021;12:701301.

[55] Cao K, Ding X, Sheng Y, Wang Y, Liu Y. Cisplatin binds to the MDM2 RING finger domain and inhibits the ubiquitination activity. Chem Commun (Camb) 2020;56(33):4599-602.

[56] Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9(10):701-13.

[57] Yu FS, Lin ML, Hsu SC, Yu CC, Huang YP, Kuo YH, et al. 4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF- $\kappa$ B and MAPK signaling pathways. Int J Oncol 2016;49(2):579-88.

[58] Ding Y, Pan Y, Liu S, Jiang F, Jiao J. Elevation of MiR-9-3p suppresses the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via down-regulating FN1, ITGB1 and ITGAV. Cancer Biol Ther 2017;18(6):414-24.

[59] Chou J, Lin YC, Kim J, You L, Xu Z, He B, et al. Nasopharyngeal carcinomareview of the molecular mechanisms of tumorigenesis. Head Neck 2008;30(7):946-63.

[60] Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007;251(1):1-16.

[61] Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, et al. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2014;25(11):2230-6.

[62] Zhang Y, Zhao Y, Liu L, Su H, Dong D, Wang J, et al. MicroRNA-19b Promotes Nasopharyngeal Carcinoma More Sensitive to Cisplatin by Suppressing KRAS. Technol Cancer Res Treat 2018;17:1533033818793652.

[63] Wang LM, Gan YH. Cancer-derived IgG involved in cisplatin resistance through PTP-BAS/Src/PDK1/AKT signaling pathway. Oral Dis 2021;27(3):464-74.

[64] Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, et al. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 2007;6(11):1379-85.

[65] Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, et al. DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res 2011;71(3):1167-76.

[66] Zhen Y, Fang W, Zhao M, Luo R, Liu Y, Fu Q, et al. miR-374a-CCND1pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin. Oncogene 2017;36(2):275-85.

[67] Alam M, Mishra R. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer. Life Sci 2021;280:119705.

[68] Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, et al. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol 2012;48(7):602-7.

[69] Yee-Lin V, Pooi-Fong W, Soo-Beng AK. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Mini Rev Med Chem 2018;18(2):173-83.

[70] VanKlompenberg MK, Bedalov CO, Soto KF, Prosperi JR. APC selectively
 mediates response to chemotherapeutic agents in breast cancer. BMC Cancer 2015;15:457.
 [71] Duan L. Parez PE. Calbour S. Maki CC. Inhibitors of Jumonii C domain

[71] Duan L, Perez RE, Calhoun S, Maki CG. Inhibitors of Jumonji C domaincontaining histone lysine demethylases overcome cisplatin and paclitaxel resistance in nonsmall cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther 2022;23(1):65-75.

[72] Ricci F, Fratelli F, Guffanti F, Porcu L, Spriano F, Dell'Anna T, et al. Patientderived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy. Oncotarget 2017;8(5):7441-51.

[73] Liu K, Jiang T, Ouyang Y, Shi Y, Zang Y, Li N, et al. Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma. Oncotarget 2015;6(18):16507-16.

[74] Wang M, Wu Q, Fang M, Huang W, Zhu H. miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1. Onco Targets Ther 2019;12:9513-25.
[75] Pei Y, Zhang Y, Zheng K, Shang G, Wang Y, Wang W, et al. targets ITGAV to suppress the proliferation and metastasis of osteosarcoma cells. Onco Targets Ther 2019;12:4499-507.

[76] Kim SH, Ho JN, Jin H, Lee SC, Lee SE, Hong SK, et al. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Investig Clin Urol 2016;57(1):63-72.

[77] Zhang C, Zhu Q, Gu J, Chen S, Li Q, Ying L. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin. Biosci Rep 2019;39(6):BSR20190381.

[78] Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, et al. MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium. Cancer Epidemiol Biomarkers Prev 2016;25(3):429-37.

[79] Xie L, Yao Z, Zhang Y, Li D, Hu F, Liao Y, et al. Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis. Cell Death Dis 2018;9(7):772.

[80] Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet 2022;38(6):613-26.

[81] Anastasiadou E, Seto AG, Beatty C, Hermreck M, Gilles ME, Stroopinsky D, et al. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth. Clin Cancer Res 2021;27(4):1139-49.

[82] Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019;88:102925.

	Proliferation					
Cell	Group	n Average $\pm$ SD		p value		
			(%)			
FaDu	Ctl_vector	4	$106.0\pm8.2$	0.55		
	ERP29	5	$101.9 \pm 10.6$			
	Ctl_siRNA	3	$107.9 \pm 1.0$	0.65		
	siERP29	5	$105.2\pm9.4$			
	ERP29	5	$101.9\pm10.6$	0.61		
	siERP29	5	$105.2\pm9.4$			
FaDu-CDDP	Ctl_vector	3	$97.2\pm4.0$	0.30		
	ERP29	3	$100.5\pm2.8$			
	Ctl_siRNA	3	$93.6\pm3.1$	0.006		
	siERP29	3	$107.9\pm3.5$			
	ERP29	3	$100.5 \pm 2.8$	0.04		
	siERP29	3	$107.9\pm3.5$			
FaDu-R	Ctl_vector	4	$99.8 \pm 12.5$	0.09		
	ERP29	4	$113.1 \pm 4.2$			
	Ctl_siRNA	3	$104.0\pm7.1$	0.24		
	siERP29	4	$110.3\pm5.7$			
	ERP29	4	$113.1 \pm 4.2$	0.46		
	si <i>ERP29</i>	4	$110.3\pm5.7$			

**Table 1** Cell proliferation in FaDu, FaDu cisplatin treated (FaDu-CDDP) and FaDucisplatin resistant (FaDu-R) cells with *ERP29* overexpression and silencing.

n: number of replicates, SD: standard deviation, Ctl\_vector: *ERP29* overexpression control, *ERP29*: cells with *ERP29* overexpression, Ctl\_siRNA: *ERP29* silencing control, si*ERP29*: cells with *ERP29* silencing.

**Table 2** Apoptosis and necrosis in FaDu, FaDu cisplatin treated (FaDu-CDDP) and FaDu cisplatin resistant (FaDu-R) cells with *ERP29* overexpression and silencing.

			Alive	Early apoptotic	Late apoptotic	Necrotic
Cell	Group	n	Average $\pm$	$Average \pm SD$	$Average \pm SD$	Average $\pm$
			SD (%)	(%)	(%)	SD (%)
FaDu	Ctl_vector	4	$78.4\pm6.7$	$18.2\pm5.8$	$2.86\pm2.0$	$0.5 \pm 0.2$
	ERP29	5	$79.8\pm6.3$	$16.8\pm5.3$	$2.3\pm0.9$	$1.3 \pm 0.2$
	p value		0.79	0.74	0.58	0.003
	Ctl_siRNA	4	$59.1\pm8.0$	$37.4\pm8.0$	$2.9\pm0.5$	$0.5 \pm 0.2$
	si <i>ERP29</i>	4	$72.2\pm8.8$	$24.3\pm8.4$	$2.9\pm0.8$	$0.6 \pm 0.1$
	p value		0.10	0.09	0.91	0.17
	ERP29	5	$79.8\pm6.3$	$16.8\pm5.3$	$2.3\pm0.9$	$1.3 \pm 0.2$
	si <i>ERP29</i>	4	$72.2\pm8.8$	$24.3\pm8.4$	$2.9\pm0.8$	$0.6 \pm 0.1$
	p value		0.17	0.14	0.30	< 0.001
FaDu- CDDP	Ctl_vector	4	$60.0 \pm 16.0$	$31.3 \pm 14.2$	$7.3 \pm 7.3$	$1.4 \pm 1.7$
	ERP29	4	$62.8 \pm 16.4$	$29.9 \pm 15.3$	$6.3\pm2.7$	$0.9 \pm 0.4$
	p value		0.84	0.89	0.59	0.67
	Ctl_siRNA	4	$50.2\pm6.0$	$44.7\pm6.5$	$4.6\pm0.9$	$0.4 \pm 0.2$
	si <i>ERP29</i>	4	$41.2\pm11.6$	$54.6 \pm 10.1$	$3.9 \pm 1.7$	$0.2\pm0.05$
	<i>p</i> value		0.22	0.15	0.49	0.04
	ERP29	4	$62.8 \pm 16.4$	$29.9 \pm 15.3$	$6.3\pm2.7$	$0.9 \pm 0.4$
	siERP29	4	$41.2\pm11.6$	$54.6 \pm 10.1$	$3.9 \pm 1.7$	$0.2\pm0.05$
	p value		0.08	0.05	0.49	0.02
FaDu- R	Ctl_vector	3	$87.7 \pm 1.2$	$10.2\pm0.6$	$1.6 \pm 0.4$	$0.5\pm0.1$
	ERP29	4	$75.9\pm7.1$	$20.9\pm7.0$	$2.2\pm0.7$	$1.1 \pm 0.4$
	p value		0.06	0.09	0.15	0.04
	Ctl_siRNA	3	$84.0\pm11.9$	$13.4\pm11.1$	$1.9\pm0.9$	$0.7\pm0.2$
	si <i>ERP29</i>	5	$78.0\pm 6.8$	$18.8\pm5.6$	$2.7\pm1.3$	$0.5\pm0.1$
	<i>p</i> value		0.39	0.39	0.36	0.03
	ERP29	4	$75.9\pm7.1$	$20.9\pm7.0$	$2.2\pm0.7$	$1.1 \pm 0.4$
	si <i>ERP29</i>	5	$78.0\pm6.8$	$18.8\pm5.6$	$2.7\pm1.3$	$0.5\pm0.1$
	<i>p</i> value		0.67	0.63	0.52	0.02

29

n: number of replicates, SD: standard deviation, Ctl\_vector: *ERP29* overexpression control, *ERP29*: cells with *ERP29* overexpression, Ctl\_siRNA: *ERP29* silencing control, si*ERP29*: cells with *ERP29* silencing.



**Fig. 1.** *ERP29* and pharynx cancer cell migration. *ERP29* silencing (si*ERP29*) decreased wound surface area when compared to *ERP29* overexpression (*ERP29*) and control (Ctl\_siRNA) in FaDu (53.5%  $\pm$  5.0% *vs* 82.7%  $\pm$  8.9%, *p*< 0.001 and 53.5%  $\pm$  5.0% *vs* 60.8%  $\pm$  3.8%, *p*= 0.04, respectively) (**A**) and FaDu cisplatin treated (FaDu-CDDP) cells (53.1%  $\pm$  4.0% *vs* 72.9%  $\pm$  7.3%, *p*= 0.02 and 53.1%  $\pm$  4.0% *vs* 62.6%  $\pm$  3.8%, *p*= 0.02, respectively) (**B**). In FaDu cisplatin resistant (FaDu-R) cells, *ERP29* silencing decreased wound surface area when compared to *ERP29* overexpression (68.2%  $\pm$  9.1% *vs* 90.3%  $\pm$  5.0%, *p*= 0.01) and *ERP29* overexpression increased wound surface area when compared to control (Ctl\_vector) (90.3%  $\pm$  5.0% *vs* 71.5%  $\pm$  13.0%, *p*= 0.04) (**C**). In LAU-2063 cells, *ERP29* silencing (si*ERP29*) decreased wound surface area when compared to control (Ctl\_siRNA) (50.7%  $\pm$  12.2% *vs* 73.7%  $\pm$  13.4%, *p*= 0.04) (**D**). \**p*< 0.05.



Fig. 2. *ERP29* and E-cadherin immunoexpression in FaDu 3D-spheroids. The blue signal represents the nuclear DNA staining by DAPI and the red signal represents E-cadherin staining. *ERP29* silencing (si*ERP29*) decreased E-cadherin immunoexpression levels when compared to negative control (Ctl\_siRNA) (54.2%  $\pm$  13.4% vs 100.0%  $\pm$  25.0%; p= 0.04). n: number of replicates,  $\mu$ m: micrometer.



Fig. 3. Differently expressed genes between *ERP29* overexpression (*ERP29*) and *ERP29* silencing (si*ERP29*) in FaDu (A), FaDu cisplatin treated (FaDu-CDDP) (B) and FaDu cisplatin resistant (FaDu-R) (C) cells. The expression of identified genes, involved in WNT, MAPK and PI3K/AKT signaling pathways (*APC*, *TCF3*; *SOS1*, *KRAS*, *MAPK1*; *ERBB2*, *SRC*, *AKT1*, *ITGAV*, *JUN*, *CCNE1*, *MDM2* and *CASP9*, respectively) was validated in FaDu (A), FaDu-CDDP (B) and FaDu-R (C).



Fig. 4. MicroRNA miR-4421 inhibitor and the expression of genes modulated by *ERP29* silencing (si*ERP29*) in FaDu (A) and FaDu cisplatin resistant (FaDu-R) (B) cells. The expression of the identified genes, involved in MAPK and PI3K/AKT signaling pathways (*SOS1*, *MAPK1*; *AKT1*, *ITGAV*, *JUN*, respectively) was analyzed. Ctl\_miR: miRNA negative control, miR-4421 inhibitor: cells transfected with miR-4421 inhibitor, n: number of replicates.